evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

4,678 questions · 4,859 findings · 283 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 1,225 · 25.2%GRADE not reported 215 · 4.4%Very low 1,241 · 25.5%Low 1,210 · 24.9%Moderate 776 · 16%High 192 · 4%

Metformin vs megestrol

Adverse effects during treatment ‐ not reported · endometrial hyperplasia

The review found no eligible studies for this question.

1 finding from 1 review

Vitamin D vs placebo

Rate of exacerbations requiring systemic corticosteroids · children and adults with predominantly mild to moderate asthma

Summary of findings table ‐ Vitamin D showed no clear difference in proportion of participants with one or more exacerbations treated… compared with placebo (high certainty).

1 finding from 1 review

Vitamin D vs placebo

Patients with severe exacerbations (requiring hospitalisation or ER visit) · children and adults with predominantly mild to moderate asthma

Summary of findings table ‐ Vitamin D showed no clear difference in proportion of participants with one or more exacerbations requiring… compared with placebo (moderate certainty).

1 finding from 1 review

Vitamin D vs placebo

Proportion of participants with one or more serious adverse events due to any cause · children and adults with predominantly mild to moderate asthma

Summary of findings table ‐ Vitamin D showed no clear difference in proportion of participants with one or more serious adverse events… compared with placebo (high certainty).

1 finding from 1 review

Vitamin D vs placebo

Withdrawals (parallel group trials/first arm cross‐over trials) · children and adults with predominantly mild to moderate asthma

Summary of findings table ‐ Vitamin D showed no clear difference in withdrawals from trial compared with placebo (high certainty).

1 finding from 1 review

Summary of findings table ‐ Rifaximin vs placebo or no intervention

Mortality ‐ total number · prevention and treatment of hepatic encephalopathy in people with cirrhosis

Summary of findings table ‐ Rifaximin showed no clear difference in mortality ‐ total number compared with placebo/no intervention (moderate certainty).

1 finding from 1 review

Summary of findings table ‐ Rifaximin vs non‐absorbable disaccharide

Hepatic encephalopathy · prevention and treatment of hepatic encephalopathy in people with cirrhosis

Summary of findings table ‐ Rifaximin showed no clear difference in hepatic encephalopathy ‐ total number compared with non‐absorbable disaccharide (low certainty).

1 finding from 1 review

Summary of findings table ‐ Rifaximin vs non‐absorbable disaccharide

Non‐serious adverse events ‐ total number of participants · prevention and treatment of hepatic encephalopathy in people with cirrhosis

It is very uncertain whether summary of findings table ‐ Rifaximin changes non‐serious adverse events ‐ total number of participants compared with non‐absorbable disaccharide (very low certainty).

1 finding from 1 review